BG9928
DrugOral 75 mg single dose
NCT Number: NCT00858156
The primary objective of the study is to evaluate the effect of hepatic function on the pharmacokinetics of a single oral dose of BG9928 in subjects with mild and moderate hepatic impairment and in subjects with normal hepatic function.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 1
Miami, Florida, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The following criteria apply only to subjects enrolled into Groups 1 and 2 (mild or moderate hepatic impairment):
Exclusion criteria
Oral 75 mg single dose
Time frame: 1 week post dose
Biogen
Industry
An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Oral BG9928 in Subjects With Mild and Moderate Hepatic Impairment and in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03289234
Healthy, Hepatic Impairment
Fukuoka, Japan
View Trial DetailsNCT04332432
Hepatic Impairment
Rialto, California, United States
View Trial DetailsNCT06736223
Hepatic Impairment
Sofia, Bulgaria
View Trial DetailsNCT06575959
Digestive System Diseases, Hepatic Impairment
Orlando, Florida, United States
View Trial Details